Eyeing a $500M peak sales pot, Almirall doubles down on lebrikizumab as Dermira lines up PhIII
With eyes on what it believes is a $500 million peak revenue opportunity in Europe, Barcelona-based Almirall has stepped up with $50 million in cash to take up the option on Dermira’s IL-13 anti-inflammatory drug lebrikizumab just ahead of the start of Phase III. And there’s another $30 million due as the late-stage program gets geared up.
That shouldn’t be long from now, as Dermira expects to begin the late-stage trial work for atopic dermatitis before the end of this year as it follows a trail that execs insist leads to blockbuster returns. Along the way, they’ll need to take on the 600-pound gorilla in atopic dermatitis: the IL-13/IL-4 drug Dupixent, from Regeneron and Sanofi. Rivals also include Leo Pharma, in its pivotal with tralokinumab, and AnaptysBio in the hunt with a mid-stage program for etokimab, previously referred to as ANB020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
